Skip to content
Screener

Tandem Diabetes Care TNDM Q1 2026 earnings

Reported May 7, 2026 · After market close

Revenue$247.2MBeat by $6.8M
EPS-$0.30Beat by $0.16
Revenue estimate$240.4M
EPS estimate-$0.46

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$266.1M
EPS estimate-$0.26

Financials

Q1 2026

Income statement

See full
Revenue$247.2M+5.5%
Gross profit$136.8M+15.5%
Operating income-$17.4M+85.6%
Net income-$20.4M+84.4%
EPS (diluted)-$0.30+84.8%

Balance sheet

See full
Cash & equivalents$179.3M+235%
Total debt$734.7M+49.0%
Total equity$132.4M-14.7%
Total assets$1.2B+25.1%

Cash flow

See full
Operating cash flow$11.1M+160%
CapEx$6.3M+111%
Free cash flow$4.8M+123%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.31B+2.8%
Enterprise value$1.87B+8.9%
P/S1.3×0.0×

Profitability

See full
Gross margin54.9%+2.7pp
Operating margin-8.2%-2.9pp
Net margin-9.2%-3.1pp

Returns & leverage

See full
Return on equity-65.7%-14.7pp
Debt / equity5.5×+2.4×
Current ratio3.6×+1.3×

Segments

By product

See full
Supplies and other$136.8M+3.4%
Pump$110.4M+8.1%

FAQ

When did Tandem Diabetes Care report Q1 2026 earnings?
Tandem Diabetes Care (TNDM) reported Q1 2026 earnings on May 7, 2026 after market close.
What were Tandem Diabetes Care's Q1 2026 revenue and EPS?
Tandem Diabetes Care reported revenue of $247.2M and eps of $-0.30 for Q1 2026.
Did Tandem Diabetes Care beat estimates in Q1 2026?
Revenue beat the consensus estimate of $240.4M by $6.8M. EPS beat the consensus estimate of $-0.46 by $0.16.
How did Tandem Diabetes Care's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 5.5% from $234.4M a year earlier and eps grew 55.2% from $-0.67.
Where can I find Tandem Diabetes Care's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001438133-26-000048) and the 10-Q periodic report (0001438133-26-000049) directly on SEC EDGAR. The filing index links above go to sec.gov.